• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Gynecologic Oncology Reports >Recurrent colon perforation after discontinuation of bevacizumab for ovarian cancer
【24h】

Recurrent colon perforation after discontinuation of bevacizumab for ovarian cancer

机译：贝伐单抗治疗卵巢癌后复发性结肠穿孔

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Bevacizumab (Bev) is an antiangiogenic drug used to treat various malignances, including ovarian cancer (OC). Bev is generally well-tolerated; however, it has a characteristic toxicity profile. In particular, gastrointestinal perforation (GIP) is a rare but serious side effect that can be lethal. A 55-year-old woman with recurrent OC had an episode of GIP during third-line chemotherapy comprising Bev and topotecan (TPT). Bev was discontinued while TPT was continued as monotherapy. Three months after discontinuation of Bev, the patient presented with left lower abdominal pain and was diagnosed with a second GIP. She had emergent surgery. One year later, she is still alive and healthy, and is continuing TPT. This is the first report of recurrent GIP after discontinuation of Bev. Our case suggests that physicians should be aware of GIP even after the discontinuation of Bev.
机译：贝伐单抗（Bev）是一种抗血管生成药物，用于治疗各种恶性肿瘤，包括卵巢癌（OC）。 Bev通常耐受性良好;但是，它具有典型的毒性特征。特别是胃肠道穿孔（GIP）是一种罕见但严重的副作用，可能致命。一名55岁的复发性OC妇女在三线化疗中（包括Bev和Topotecan（TPT））发生了GIP发作。在继续TPT单一疗法的同时停用Bev。 Bev停用三个月后，患者出现左下腹疼痛，并被诊断出患有第二次GIP。她接受了紧急手术。一年后，她仍然活着并且健康，并且正在继续进行TPT。这是中止Bev后复发性GIP的首次报道。我们的案例表明，即使在停用Bev后，医生也应注意GIP。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号